Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Westport, CT, Nov.  26, 2019  (GLOBE NEWSWIRE) --    ·New areas of collaboration identified between Mayo Clinic and BioSig

BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic

Westport, CT, Nov.  21, 2019  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company commenced its first clinical trial for its PURE EP™ System.

BioSig Commences Clinical Trial Enrollment for PURE EP System

BioSig Supports the Alliance for Advancing Bioelectronic Medicine,  Which Seeks to Bring Together Leading Experts to Advance Entire Field BioSig Supports the Alliance for Advancing Bioelectronic Medicine,  Which Seeks to Bring Together Leading Experts to Advance Entire Field

BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine Alliance

Highlights include PURE EP™ System commercialization plans for 2020, clinical trial and installation updates on PURE EP™ System and other business development advancements Highlights include PURE EP™ System commercialization plans for 2020, clinical trial and installation updates on PURE EP™ System and other business development advancements

BioSig Technologies Issues November 2019 Shareholder Letter

Westport, CT, Nov.  07, 2019  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company’s founder, Chairman & CEO Kenneth L. Londoner is making a gift to New York-based Union College in order to support the school’s growing internship program. 

BioSig Technologies Invests in Union College’s Internship Program

Former Investment Officer at Mayo Clinic to oversee relationships in the Midwest Former Investment Officer at Mayo Clinic to oversee relationships in the Midwest

Sasha Gentling, CFA Joins BioSig as Director of Business Development

Capital markets professional to grow institutional relationships Capital markets professional to grow institutional relationships

BioSig Appoints Andrew Ballou as Vice President of Investor Relations

The Company joins leading medtech peers in Destination Medical Center’s Discovery Square The Company joins leading medtech peers in Destination Medical Center’s Discovery Square

BioSig Opens a Technology Development Office in Rochester, MN

Westport, CT, Oct.  10, 2019  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be exhibiting at the 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy on October 11-12, 2019 at Hyatt at the Bellevue in Philadelphia, PA.

BioSig to Participate at The 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy

PALM BEACH, Fla., Sept.  12, 2019  (GLOBE NEWSWIRE) -- According to a recent market research report  published  by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based views crucial for building business intelligence and overcoming market challenges, "the global electrophysiology devices market size was valued at $5.1 Billion in 2018.  Increasing use of electrophysiology devices in the diagnosis and treatment of cardiovascular diseases such as atrial fibrillation, growing demand for cardiac rhythm management devices for continuous monitoring and increasing use of these devices in out-of-hospital settings are some high impact rendering growth drivers of the market."  Active healthcare stocks in news today include:  BioSig Technologies, Inc. (NASDAQ:BSGM), Amarin Corporation plc (NASDAQ: AMRN), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN),  Aimmune Therapeutics, Inc. (NASDAQ: AIMT).

Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

Coda Octopus Group

Everbridge

GW Pharmaceuticals

Rent-A-Center

Zynex Inc

Despite May's large losses, these stocks to buy made new 52-week highs. Maybe this is a signal that they will continue to head higher.

7 Stocks to Buy That Are Near 52-Week Highs

BioSig's Pure EP System is a game changer.

BioSig Technologies Pivotal Moment

News for Biosig Technologies Inc Stock (BSGM)